Sodium‐glucose cotransporter type 2 channel inhibitor: Breakthrough in the treatment of neutropenia in patients with glycogen storage disease type 1b?

Sodium‐glucose cotransporter type 2 channel inhibitor: Breakthrough in the treatment of neutropenia in patients with glycogen storage disease type 1b?

Abstract Glycogen storage disease type 1b (GSD 1b) is an inherited metabolic defect caused by biallelic mutations in the SLC37A4 gene encoding microsomal glucose‐6‐phosphate (G6P) transporter in the endoplasmic reticulum (ER) membrane. Ineffective G6P transport into the ER leads to hypoglycaemia, hy...

Full description

Bibliographic Details
Main Authors: Magdalena Kaczor, Milena Greczan, Karolina Kierus, Ewa Ehmke vel Emczyńska‐Seliga, Elżbieta Ciara, Barbara Piątosa, Dariusz Rokicki, Janusz Książyk, Dorota Wesół‐Kucharska
Format: Article
Language:English
Published: Wiley 2022-05-01
Series:JIMD Reports
Subjects:
empagliflozin
G‐CSF
GSD 1b
neutropenia
SGLT2 inhibitor
Online Access:https://doi.org/10.1002/jmd2.12278

Internet

https://doi.org/10.1002/jmd2.12278

Similar Items